GLP-1 (1-37) (human, rat, mouse, bovine) (trifluoroacetate salt)
(Synonyms: 胰高血糖素样肽-1（GLP-1）,Glucagon-like Peptide-1) 目录号 : GC43761GLP-1 (1-37) (human, rat, mouse, bovine) (trifluoroacetate salt)是由肠道分泌的胰高血糖素样肽-1的全长前体。
Cas No.:87805-34-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
GLP-1 (1-37) (human, rat, mouse, bovine) (trifluoroacetate salt) is a full-length precursor form of glucagon-like peptide-1 secreted by the intestine [1]. GLP-1 (1-37) itself has low activity and does not directly activate the GLP-1 receptor. It is mainly used to study the processing mechanism of GLP-1, structure-function analysis, cross-species comparison, and the development of new GLP-1 receptor agonists [2-3].
In CD4-positive lymphocytes, GLP-1 (1-37) (1nM; 30min) reduces chemokine-induced migration of CD4-positive lymphocytes [4].
In C57BL/6 pregnant mice, GLP-1 (1-37) (10nM; ip; 8d) converts developing intestinal epithelial cells into insulin-producing cells in vivo [5].
References:
[1]. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine reviews. 1995 Jun 1; 16(3): 390-410.
[2]. KAWAI K, SUZUKI S, OHASHI S, et al. Comparison of the effects of glucagon-like peptide-1-(1-37) and-(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology. 1989 Apr 1; 124(4): 1768-1773.
[3]. Vahl TP, Paty BW, Fuller BD, et al. Effects of GLP-1-(7–36) NH2, GLP-1-(7–37), and GLP-1-(9–36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. The Journal of Clinical Endocrinology & Metabolism. 2003 Apr 1; 88(4): 1772-1779.
[4]. Marx N, Burgmaier M, Heinz P, et al. Glucagon-like peptide-1 (1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cellular and molecular life sciences. 2010 Oct; 67: 3549-3555.
[5]. Suzuki A, Nakauchi H, Taniguchi H. Glucagon-like peptide 1 (1–37) converts intestinal epithelial cells into insulin-producing cells. Proceedings of the National Academy of Sciences. 2003 Apr 29; 100(9): 5034-5039.
GLP-1 (1-37) (human, rat, mouse, bovine) (trifluoroacetate salt)是由肠道分泌的胰高血糖素样肽-1的全长前体 [1]。GLP-1 (1-37)本身活性较低，不直接激活GLP-1受体。主要用于研究GLP-1的加工机制、结构-功能分析、跨物种比较以及新型GLP-1受体激动剂的开发 [2-3]。
在CD4阳性淋巴细胞中，GLP-1 (1-37)（1nM；30分钟）可降低趋化因子诱导的CD4阳性淋巴细胞迁移 [4]。
在C57BL/6怀孕小鼠中，GLP-1 (1-37)（10nM；ip；8d）可将发育中的肠上皮细胞转化为体内产生胰岛素的细胞 [5]。
| Cell experiment [1]: | |
Cell lines | CD4-positive lymphocytes |
Preparation Method | After isolation, CD4-positive lymphocytes were cultured in serum-free media for 16h. T-cell chemotaxis was assayed under serum-free conditions in a 48-well microchemotaxis chamber (Neuroprobe). Wells in the upper and lower chamber were separated by a polyvinylpyrrolidone-free polycarbonate membrane (pore size 5μm; Costar). CD4-positive cells at a density of 5 × 106/mL were pretreated for 30min with GLP-1 (1-37) at the concentrations indicated before 3h of incubation with SDF-1 or RANTES. |
Reaction Conditions | 1nM; 30min |
Applications | GLP-1 (1-37) reduces chemokine-induced migration of CD4-positive lymphocytes. |
| Animal experiment [2]: | |
Animal models | C57BL/6 pregnant mice |
Preparation Method | GLP-1 (1-37) was intraperitoneally injected into C57BL/6 pregnant mice at 10nM/day for 8 days. After daily injection, the jejunum, ileum, and colon were analyzed by immunohistochemistry. |
Dosage form | 10nM; ip; 8d |
Applications | GLP-1 (1-37) converts developing intestinal epithelial cells into insulin-producing cells in vivo. |
References: | |
| Cas No. | 87805-34-3 | SDF | |
| 别名 | 胰高血糖素样肽-1（GLP-1）,Glucagon-like Peptide-1 | ||
| 化学名 | glucagon-like peptide I (human, rat, mouse, bovine), trifluoroacetate salt | ||
| Canonical SMILES | [H]N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@ | ||
| 分子式 | C186H275N51O59 • XCF3COOH | 分子量 | 4169.5 |
| 溶解度 | 1 mg/ml in water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2398 mL | 1.1992 mL | 2.3984 mL |
| 5 mM | 0.048 mL | 0.2398 mL | 0.4797 mL |
| 10 mM | 0.024 mL | 0.1199 mL | 0.2398 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet